Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
MBG453 - TIM-3 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
NCT03946670 STIMULUS MDS-1 (CMBG453B12201)
Myelodysplastic syndrome
Phase 2
120
Complete Remission (CR) rate and Progression Free Survival (PFS)
Experimental: Sabatolimab (MBG453) + hypomethylating agents
Placebo comparator: Placebo + hypomethylating agents
Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome
(MDS) as per IPSS-R criteria
2022-2023
NCT04266301 STIMULUS-MDS2 (CMBG453B12301)
Myelodysplastic syndrome
Phase 3
500
Overall survival
Sabatolimab 800 mg + azacitidine 75 mg/m2
Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo
Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS)
as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
2023
Publication
TBD
107 Investor Relations | Q2 2021 Results
TBD
NOVARTIS | Reimagining MedicineView entire presentation